ÖNDER ÖZCAN, Ahmet Korkut BELLİ, SELAMİ ILGAZ KAYILIOĞLU, ÖZGÜR İLHAN ÇELİK, MEHMET KAPLAN, Murat KARA, Murat POLAT

Does MiRNA gene expression predict gastric cancer stage and localization?

Gastric cancer comprises 10% of all cancers in the world and is rarely seen before the age of 30. Different genetic interactions or molecular changes like e-cadherin, P16, APC, c-erb B2, c-met, ras, or c-myc have been described in the pathogenesis of the disease. MiRNAs play critical roles in various biological processes such as cell proliferation, cell differentiation, apoptosis, repairing of DNA damage, angiogenesis, stress response, and stem cell division. The aim of this study is to investigate the relationship between miRNA gene expressions and gastric cancer. Method: Sixty-four patients with gastric cancer diagnosed consecutively in our pathology laboratory and 30 consecutive participants with normal gastric tissue, as a control group, were included in our study between 2011 and 2013. Total miRNAs were obtained by using genomic miRNA extraction kit (QIAGEN Sample & Assay Technologies, Hilden, Germany) after the samples had been deparaffinized. MiR-21, 107, 141, 150, 192, 202, 218, 331 gene expressions were evaluated by using real time-PCR (RT-PCR) from the whole miRNA. Results: MiR-331 was downregulated in the stage 2 patients and the rest of the miRNAs were significantly upregulated (p < 0.001). All miRNAs were significantly upregulated in the stage 3a patients (p < 0.001). In the antrum localized tumors, miR-107, -150, -202, -218, and -331 were significantly upregulated, whereas miR-21, -192 were statistically downregulated (p < 0.05). In the cardia localized tumors, miR-21 (p > 0.05) was downregulated and miR-107, -150, -202, -218, and -331 were upregulated (p < 0.05) Different gene expressions of miRNAs according to the different localizations of gastric cancer and different stages suggest that it can be tumor marker to predict the stage and localization of gastric cancer.

PDF

___

Peter Boyle, Bernard Levin, editors. World cancer report. International Agency for Research on Cancer. Lyon: 2008.

Toyoda T, Tsukamoto T, Yamamoto M, et al. Gene expression analysis of a Helicobacter pylori-infected and high-salt diet-treated mouse gastric tumor model: identification of CD177 as a novel prognostic factor in patients with gastric cancer. BMC Gastroenterol. 2013;13:122.

Silvera SAN, Mayne ST, Gammon MD, et al. Diet and lifestyle factors and risk of subtypes of esophageal and gastric cancers: classification tree analysis. Ann Epidemiol. 2014;24:50-57.

Jin Z, Jiang W, Wang L. Biomarkers for gastric cancer: Progression in early diagnosis and prognosis. Oncol Lett. 2015 9:1502-08.

Nobili S, Brun L, Landini I, et al. Genomic and genetic alterations influence the progression of gastric cancer. World J Gastroenterol. 2011;17:290.

Salloum FN, Yin C, Kukreja RC. Role of microRNAs in cardiac preconditioning. J Cardiovasc Pharmacol. 2010;56:581-88.

Lee DY, Deng Z, Wang CH, et al. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci U S A. 2007;104:20350-5.

Li LJ, Gao LB, Lv ML, et al. Association betweenSNPs in pre-miRNA and risk of chronic obstructive pulmonary disease. Clin Biochem. 2011;44:813-16.

Jiang C, Chen X, Alattar M, et al. MicroRNAs in tumorigenesis, metastasis, diagnosis and prognosis of gastric cancer. Cancer Gene Ther. 2015;22:291-301

Nana-Sinkam SP, Croce CM. MicroRNAs as therapeutic targets in cancer. Transl Res. 2011;157:216-25.

Du L, Pertsemlidis A. microRNAs and lung cancer: tumors and 22-mers. Cancer Metastasis Rev. 2010;29:109-22. Conclusion 12. Sobin LH, Fleming ID. TNM classification of malignant tumors. Cancer: Interdisciplinary. Intern J Am Cancer Society 1997;80:1803-4.

Gobbi PG, Villano L, Pozzoli D, et al. Improving the AJCC/TNM classification for use in early gastric cancer. Journal of Gastrointestinal Surgery. 2011;15:935-41.

Tsukamoto Y, Nakada C, Noguchi T, et al. MicroRNA-375 Is Downregulated in Gastric Carcinomas and Regulates Cell Survival by Targeting PDK1 and 14-3-3ζ. Cancer Res. 2010;70:2339-49.

Leichter AL, Sullivan MJ, Eccles MR, et al. MicroRNA expression patterns and signalling pathways in the development and progression of childhood solid tumours. Molecular cancer. 2017;16:15.

Feng R, Chen X, Yu Y, et al. miR-126 functions as a tumour suppressor in human gastric cancer. Cancer Lett. 2010;298:50-63.

Li X, Zhang Y, Shi Y, et al. MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. Oncogene. 2010;30:1577.

Dong G, Liang J, Han Y, et al. MicroRNA-107, an oncogene microRNA that regulates tumor Invasion and metastasis by targeting DICER1 in gastric cancer: MiR-107 promotes gastric cancer invasion and metastasis. J Cell Mol Med. 2011;15:1887-95.

Garzon R, Volinia S, Liu CG, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute my¬eloid leukemia. Blood. 2008;111:3183-9

Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006;103:2257-61.

Meng F, Henson RH, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterol. 2007;133:647–58.

Akagi I, Miyashita M, Ishibashi O, et al. Relationship between altered expression levels of MIR21, MIR143, MIR145, and MIR205 and clinicopathologic features of esophageal squamous cell carcinoma. Dis Esophagus. 2011;24:523-30.

Li X, Zhang Y, Shi Y, et al. MicroRNA-107, an oncogene MicroRNA that regulates tumor invasion and metastasis by targeting DICER1 in gastric cancer: MiR-107 promotes gastric cancer invasion and metastasis. J Cell Mol Med. 2011;15:1887-95.

Feng L, Xie Y, Zhang H, et al. miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells. Med Oncol. 2012;29:856-63.

Chiang Y, Song Y, Wang Z, et al. microRNA-192, -194 and -215 are frequently downregulated in colorectal cancer. Exp Ther Med. 2012;3:560-6.

Xu YJ, Fan Y. MiR-215/192 participates in gastric cancer progression. Clin Transl Oncol. 2015;17:34-40.